Médecine

Paramédical

Autres domaines


Suscribirse

Existing highly accumulating lysosomotropic drugs with potential for repurposing to target COVID-19 - 27/10/20

Doi : 10.1016/j.biopha.2020.110582 
Ulf Norinder a, b, Astrud Tuck c, Kalle Norgren c, Vesna Munic Kos c,
a Department of Computer and Systems Sciences, Stockholm University, Box 7003, SE-164 07 Kista, Sweden 
b MTM Research Centre, School of Science and Technology, Örebro University, SE-701 82 Örebro, Sweden 
c Department of Physiology and Pharmacology, Karolinska Institutet, SE-171 77 Stockholm, Sweden 

Corresponding author at: Department of Physiology and Pharmacology, Karolinska Institutet, Solnavägen 9, SE-171 77 Stockholm, Sweden.Department of Physiology and PharmacologyKarolinska InstitutetSolnavägen 9StockholmSE-171 77Sweden

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

Graphical abstract




El texto completo de este artículo está disponible en PDF.

Highlights

Lysosomotropic drugs show moderate antiviral effects even on coronaviruses.
The antiviral activity is likely due to interference with endosomal pathway.
530 existing drugs were analysed for lysosomotropism, pharmacokinetics and toxicity.
36 drugs were identified that may possibly be suitable for repurposing for COVID-19.
Further research is needed to confirm their antiviral effects and safety limits.

El texto completo de este artículo está disponible en PDF.

Abstract

Given the speed of viral infection spread, repurposing of existing drugs has been given the highest priority in combating the ongoing COVID-19 pandemic. Only drugs that are already registered or close to registration, and therefore have passed lengthy safety assessments, have a chance to be tested in clinical trials and reach patients quickly enough to help in the current disease outbreak.

Here, we have reviewed available evidence and possible ways forward to identify already existing pharmaceuticals displaying modest broad-spectrum antiviral activity which is likely linked to their high accumulation in cells. Several well studied examples indicate that these drugs accumulate in lysosomes, endosomes and biological membranes in general, and thereby interfere with endosomal pathway and intracellular membrane trafficking crucial for viral infection. With the aim to identify other lysosomotropic drugs with possible inherent antiviral activity, we have applied a set of clear physicochemical, pharmacokinetic and molecular criteria on 530 existing drugs. In addition to publicly available data, we have also used our in silico model for the prediction of accumulation in lysosomes and endosomes. By this approach we have identified 36 compounds with possible antiviral effects, also against coronaviruses. For 14 of them evidence of broad-spectrum antiviral activity has already been reported, adding support to the value of this approach.

Presented pros and cons, knowledge gaps and methods to identify lysosomotropic antivirals, can help in the evaluation of many drugs currently in clinical trials considered for repurposing to target COVID-19, as well as open doors to finding more potent and safer alternatives.

El texto completo de este artículo está disponible en PDF.

Abbreviations : ACC, CAD, ER, PLD, Vd, logP, pKa, hERG, QSAR, CCR5

Keywords : COVID-19, Antiviral drugs, Drug repositioning, Lysosomotropism, Endosomal pathway, Broad spectrum antivirals


Esquema


© 2020  The Author(s). Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 130

Artículo 110582- octobre 2020 Regresar al número
Artículo precedente Artículo precedente
  • PARP-inhibitors in a non?oncological indication as COVID-19: Are we aware about its potential role as anti-thrombotic drugs? The discussion is open
  • Ettore Capoluongo
| Artículo siguiente Artículo siguiente
  • Syzygium aromaticum (clove) and Thymus zygis (thyme) essential oils increase susceptibility to colistin in the nosocomial pathogens Acinetobacter baumannii and Klebsiella pneumoniae
  • Juan C. Vázquez-Ucha, Marta Martínez-Guitián, Cristina Lasarte-Monterrubio, Kelly Conde-Pérez, Jorge Arca-Suárez, Laura Álvarez-Fraga, Astrid Pérez, José Crecente-Campo, María J. Alonso, Germán Bou, Margarita Poza, Alejandro Beceiro

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.